Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13201540 | 0.88 | NPSR1 (0.42) | L3MBTL1NPSR1HPGDALDH1A1LMNA | |
| SCHEMBL19652463 | 0.78 | CYP1A2 (0.38) | NPSR1HPGDALDH1A1LMNAKMT2A | |
| SCHEMBL29561964 | 0.78 | CYP1A2 (0.38) | NPSR1HPGDALDH1A1LMNAKMT2A | |
| SCHEMBL13218642 | 0.77 | HPGD (0.33) | NPSR1HPGDALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL29636346 | 0.77 | PTGES (0.43) | L3MBTL1HPGDALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1128663 | 0.77 | KMT2A (0.32) | NPSR1HPGDALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL12436062 | 0.77 | PTGES (0.40) | L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14617245 | 0.77 | PTGES (0.43) | L3MBTL1HPGDALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL18185855 | 0.75 | HPGD (0.42) | L3MBTL1HPGDALDH1A1KMT2ACYP2C19 | |
| SCHEMBL31330611 | 0.75 | EGLN1 (0.42) | HPGDALDH1A1LMNASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331054-B2 | Perk inhibiting imidazolopyrazine compounds | HIBERCELL, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20220348583-A1 | PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS | HIBERCELL, INC. | 2022-11-03 | — | — | US | disclosed |
| US-20220348584-A1 | PERK INHIBITING INDOLINYL COMPOUNDS | HIBERCELL, INC. | 2022-11-03 | — | — | US | disclosed |
| WO-2021231784-A1 | PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS | HIBERCELL, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021041976-A1 | PERK INHIBITING INDOLINYL COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021041970-A1 | PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348583-A1 | PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS | MAPKAPK2, MAPK4, MAP3K5 | L3MBTL1 1962/4885NPSR1 4552/4885HPGD 2009/4885 |
| US-12331054-B2 | Perk inhibiting imidazolopyrazine compounds | MAPKAPK2, MAPK4, MAP3K5 | L3MBTL1 1962/4885NPSR1 4552/4885HPGD 2009/4885 |
| US-20220348584-A1 | PERK INHIBITING INDOLINYL COMPOUNDS | ATF4, MAP3K10, EEF2K | L3MBTL1 1387/4885NPSR1 4109/4885HPGD 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.